| U |
|
Ultrasound improves myocardial perfusion in a canine model of myocardial infarction
|
| Suchkova V., Francis C. W., Luo H., Baggs R. B., Miyamoto T., Siegel R. J. |
| |
|
Ultrastructural changes in platelets after surgical manipulations in pigs liver
|
| Helmy A., El Khafif N., Said S., Yehia H., Keshta S. |
| |
|
Underlying platelet function disorders and von Willebrand disease in children with epistaxis or menorrhagia
|
| Rand M. L., Clark D., Schmugge M., Wakefield C., Blanchette V. S. |
| |
|
Understanding thrombin
|
| Leung L. |
| |
|
Unexpected pattern of hypercoagulable states in patients with patent foramen ovale (PFO) or atrial septal defect (ASD) and neurological events
|
| Hassell K., Dodge S., Keller J., Groves B., Carroll J. |
| |
|
Unfractionated heparin, but not a low-molecular-weight heparin (Clivarin), mediates differential generation of anti-heparin-PF4 antibodies in orthopedic surgery patients: Pathophysiologic and pharmacologic implications
|
| Ahmad S., Haas S., Bacher P., Misselwitz F., Reid U., Hoppensteadt D. A., Fareed J. |
| |
|
Unresolved issues in anticoagulant therapy
|
| Schulman S. |
| |
|
Unusual persistent cell damages in irradiated rat endothelium as a model in study pathophysiology of atherosclerosis and thrombosis
|
| Fedortseva R. F., Stepanov R. P., Nikiforov A. M., Bychkovskaya I. B. |
| |
|
Up-regulation of plasminogen activator inhibitor-1 (PAI-1) by thymosinb 4 in endothelial cells
|
| Al-Nedawi K., Szemraj J., Bednarek R., Swiatkowska M., Cierniewska-Cieslak A., Dastych J., Wyczolkowska J., Cierniewski C. S. |
| |
|
Urokinase induced fibrinolysis in thromboelastography (UKIFTEG): a new assay for determining fibrinolysis in whole blood
|
| Jones D. W., Gallimore M. J., Tappenden K., Winter M. |
| |
|
Urokinase receptor (uPAR) regulates integrin redistribution during initial vascular endothelial growth factor (VEGF)-induced endothelial cell migration
|
| Prager G. W., Breuss J., Steurer S., Kadl A., Mihaly J., Binder B. R. |
| |
|
Use of a decision-making system based on the Fuzzy sets theory applied to the routine of results' release in the haemostasis laboratory: how to do it better and quicker
|
| Franco R. F., Matos M. F., Garcia P. F., Fontes F. S., Gomide F., Molina J. F., Figueiredo M. S., Villela M. S. H., Vieira J. G. H., Ghiringhello M. T. |
| |
|
Use of aprotinin as an antidote in activated protein C related bleeding
|
| Madlener K., Mueller J., Poetzsch B. |
| |
|
Use of constant infusion of recombinant factor VIIa (NovoSeven) in the management of a recurrent subdural hematoma in a patient with severe hepatic coagulopathy
|
| Nolen J. D. L., Duncan A., Martinez E., Iyengar S. |
| |
|
Use of danaparoid sodium for continuous renal replacement therapy in intensive care patients
|
| Lindhoff-Last E., Betz C., Bauersachs R. |
| |
|
Use of different d-dimer levels to exclude venous thromboembolism depending on clinical pretest probability
|
| Linkins L. A., Bates S. M., Ginsberg J. S., Kearon C. |
| |
|
Use of double virus-inactivated factor VIII concentrate (Immunate®) as treatment of von Willebrand disease
|
| Leebeek F. W. G., Verelst K., Kappers-Klunne M. C., Van Vliet H. H. D. M. |
| |
|
Use of LMWHs in patients with cancer
|
| Baranski A. |
| |
|
Use of LMWHs in patients with renal impairment
|
| Bergmann J.F. |
| |
|
Use of LMWHs in pediatric patients
|
| Massicotte P. |
| |
|
Use of low molecular weight heparin in children with thromboembolic events; predictors for bleeding and recurrence on therapy
|
| Revel-Vilk S., Sharathkumar A., Chan A. K. C., Marzinotto V., Massicotte P. |
| |
|
Use of plasma spiked with monoclonal antibodies in lupus anticoagulant (LA) screening; experience with the UK NEQAS (Blood Coagulation) proficiency testing program
|
| Jennings I., Arnout J., Kitchen S., Cartwright I., Woods T. A. L., Preston F. E. |
| |
|
Use of prophylaxis as routine management and surgical cover for patients with haemophilia
|
| Abshire T. |
| |
|
Use of recombinant activated factor VII (NovoSeven) in patients with liver cirrhosis
|
| Oltean G., Demian S., Macarie I., Bataga S., Candea M. C., Georgescu D. |
| |
|
Use of recombinant activated factor VII (rFVIIa) for management of postoperative bleeding in patients with idiopathic thrombocytopenic purpura (ITP)
|
| Shulutko E., Gorodetsky V., Galstyan G. |
| |
|
Use of recombinant factor VIIa in severe acquired coagulopathies in childhood
|
| Hassenpflug W., Rischewski J., Hellwege H. H., Zander A. R., Schneppenheim R. |
| |
|
Use of specific reference ranges for equal volume mixing studies in lupus anticoagulant assays
|
| Moore G. W., Mccarthy C. J., Savidge G. F. |
| |
|
Use of SSC/ISTH secondary standard to evaluate laboratory performance: A UK NEQAS for blood coagulation proficiency testing exercise
|
| Woods T. A. L., Jennings I., Kitchen S., Kitchen D. P., Preston F. E. |
| |
|
Use of TEG® as a global measure of thrombogenicity in thrombophilia screening
|
| O'Donnell J., Riddell A., Perry D. J. |
| |
|
Use of umbilical cord vein in an in vitro perfusion model to study blood-borne metastasis
|
| Sehgal L. R., Eldibany M., Wong J., Wood T., He J., Caprini J. A. |
| |
|
Usefulness of fully automated measurement of reticulated platelet using the whole blood
|
| Sakakura M., Wada H. W., Nobori T. N., Abe A. Y., Nishioka J. N., Oguni S. O., Hamaguchi Y. H. |
| |
|
Usefulness of the prothrombin level measured by the carinactivase-1 method as the parameter of the coagulation activity during chronic warfarin therapy
|
| Iwade K., Aosaki M., Tatsumi F., Matsuo T., Sekino T., Katsume T., Morita T. |
| |
|
Using a modified thrombin generation assay for potency assessment of B-domain deleted recombinant factor VIII (ReFacto®)
|
| Bassus S., Scholz T., Wegert W., Mahnel R., Kirchmaier C. M. |
| |
|
Using ETP to predict which factor V Leiden heterozygotes will suffer from venous thrombo-embolism
|
| Seldon M., Lincz L., Lonergan A., Scourgie F., Rowlings P., Gibson R., Lawrie A. |
| |
|
Using NovoSeven (NS) – recombinant factor VIIa to control the bleedings in Bernard-Soulier (BSS) girl. Case report
|
| Vdovin V. V., Larina L. E., Plahuta T. G., Donush E. K., Haspekova S. G., Soskov G. I. |
| |
|
Utility of in vitro closure time (PFA-100TM) for evaluating platelet related primary hemostasis in dialysis patients
|
| Salobir B., Preloznik-Zupan I., Sabovic M., Buturovic-Ponikvar J., Cernelc P. |
| |
|
Utility of PFA-100 in pediatric patients referred for evaluation of bleeding symptoms
|
| Domm J. A., Galiani D., Janco R. L. |
| |
|
Utilization of monoclonal antibodies for the quantification of molecular markers of hemostasis
|
| Lugovskoy E., Kolesnikova I. M., Gritsenko P. G., Komisarenko S. V. |
| |
